Plain-English translation of NCT06751303 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a precision medicine approach — using genetic testing of your tumor — can help ovarian cancer patients make better decisions about maintenance therapy with niraparib. Researchers want to understand how well this medication works for different patients and, more importantly, how it affects your quality of life during treatment. The goal is to help future patients and their doctors decide whether the benefits of this treatment are worth the side effects.
Two different medications can help prevent ovarian cancer from coming back after chemotherapy, but one causes significantly more side effects than the other. This study exists to figure out which patients will truly benefit from this medication and which might be better off choosing a different path — so doctors can give patients personalized, honest recommendations rather than one-size-fits-all advice.
You likely qualify if…
You likely don't qualify if…
You will have genetic testing performed on your ovarian cancer tumor to see how well your cancer cells can repair their own DNA — this test guides your treatment options. Depending on your test results, you may receive a decision-aid tool to help you and your doctor talk through whether the medication is right for you. Throughout the study, you will complete questionnaires about your quality of life, side effects, and how the treatment is working, allowing researchers to track real-world outcomes in Saskatchewan.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Canada